Tags » People Places Events

Why Bad Doctors Are Like Bad Writers: The Curse Of Knowledge

Steven Pinker, the Harvard psychologist and best-selling author, has a wonderful essay in the Wall Street Journal about why smart people are so often bad writers. 95 more words

Policy & Ethics

New England Journal Of Medicine Declines To Retract Papers From Disgraced Research Group

Like the Leaning Tower of Pisa, the two New England Journal of Medicine papers by disgraced Dutch researcher Don Poldermans will never stand straight. But like the famous Tower they are also unlikely to topple anytime soon. 62 more words

Policy & Ethics

Embattled HDL Laboratory CEO Resigns Amid Federal Investigation

Tonya Mallory, the embattled President and CEO of troubled Health Diagnostics Laboratory, has resigned her positions, the company announced today. Mallory said she was leaving to help her brother start a new business. 85 more words

Policy & Ethics

A 'Disappeared' Article, Finally Published, Finds A Desultory Response To Scientific Misconduct

Back in January an article in the European Heart Journal raising the disturbing possibility that guidelines based on fraudulent research may have been responsible for as many as 800,000 deaths was  122 more words

Policy & Ethics

Cardiology Group Withdraws 'Choosing Wisely' Recommendation

In the end it wasn’t wisdom for the ages. The American College of Cardiology said today that it was withdrawing one of its five recommendations in  103 more words

Policy & Ethics

Amarin Says It Will Complete Cardiovascular Outcomes Trial For Its Fish Oil Pill

After nearly a year of uncertainty, Amarin  announced  its commitment to complete REDUCE-IT  (Reduction of Cardiovascular Events with EPA – Intervention Trial). The trial is designed to test the effects on cardiovascular outcomes of Vascepa, the company’s high EPA omega-3 prescription fish oil product, in people with moderately elevated triglyceride levels between 200-499 mg/dL. 40 more words

Policy & Ethics

Japanese Research Scandal Involving Novartis Blood Pressure Drug Widens

The Japanese scandal over research using the Novartis blockbuster hypertension drug Diovan (valsartan) continues to widen. The first major figure brought down in the scandal was  90 more words

Policy & Ethics